Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 8, 2007

Primary Completion Date

July 22, 2008

Study Completion Date

July 22, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

SB-656933-AAA

SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.

DRUG

Placebo

Placebo tablets will be intended to be administered orally.

Trial Locations (1)

GSK Investigational Site, Berlin